Biosimilar Index Podcast: Interview with Dr Paul Calvo, IP and Legal Expert

This complimentary podcast is a Q&A with Dr Paul Calvo, a leading expert on the legal and intellectual property (IP) issues within the US biosimilars market.

The interview focuses on the following areas:

• Current status of the US biosimilars market
• Status of litigation and strategies being used to challenge originator biologics’ patents
• The future direction of the US biosimilars market, and how litigation has the potential to shape the market

This podcast is one of the many information sources you have access to when purchasing access to FirstWord’s Biosimilar Index.

FirstWord's Biosimilar Index is a comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Request a demo today

Biosimilar Index now includes over 520 biosimilar and NCB programmes and is segmented by developing company,  reference molecule, market status and therapeutic class, making it one of the most detailed biosimilar market tracking tools available today.

Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.

Biosimilar Index provides a collection of key journal articles, news stories, key regulatory developments, licensing availability and partnering information for all key programmes. All information is sorted in an easy-to-search tab of the datafile with links to source information.

Request a demo today